- Malattie cardiache
- Parkinson
- GvHd
- Lesioni spinali
- Ictus cerebrali
- Degenerazione dei nuclei della base (MSA, PSP, Huntington, Tourette)
- Alzheimer
- Malattie autoimmuni
- Danni renali
- Sclerosi multipla
- Diabete Mellito di tipo I
- Osteogenesi Imperfetta e difetti osseo-cartilaginei
- Lupus eritematoso sistemico
- Transplantologia
11 Terapia cellulare nel danno ischemico
Cell-based therapy in ischemic stroke.
Expert Rev Neurother. 2008 Aug;8(8):1193-201.
Hess DC, Borlongan CV.
Department of Neurology, Medical College of Georgia, Augusta, GA 30912, USA. [email protected]
Abstract
Cell-based therapy for stroke represents a third wave of therapeutics for stroke and one focused on restorative processes with a longer time window of opportunity than neuroprotective therapies.
An early time window, within the first week after stroke, is an opportunity for intravenously delivered bone marrow and perinatally derived cells that can home to areas of tissue injury and target brain remodeling.
Allogeneic cells will likely be the most scalable and commercially viable product. Later time windows, months after stroke, may be opportunities for intracerebral transplantation of neuronally differentiated cell types. An integrated approach of cell-based therapy with early-phase clinical trials and continued preclinical work with focus on mechanisms of action is needed.
Ann Neurol. 2005 Jun;57(6):874-82
